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Objective. The aim of this study was to demonstrate the immunohistochemical profile of oral inflammatory
myofibroblastic tumors (IMTs) along with morphologic analysis.
Study design. Three cases diagnosed as oral IMTs were selected to compile an immunohistochemical panel
constituted by calponin, caldesmon, Bcl-2, desmin, fibronectin, CD68, Ki-67, S100, anaplastic lymphoma kinase
(ALK), –smooth muscle actin, cytokeratins AE1/AE3, muscle-specific actin, CD34, and vimentin. An oral squamous
cell carcinoma with a focal area of desmoplastic stroma was used as control for the stained myofibroblastic cells.
Results. All oral IMTs were positive for calponin, revealing a strong and diffuse expression in the spindle-shaped cells.
The lesions were also positive for vimentin (3/3), fibronectin (3/3), –smooth muscle actin (3/3), and muscle-specific
actin (1/3) and negative for h-caldesmon, Bcl-2, desmin, CD68, Ki-67, S100, ALK, cytokeratins AE1/AE3, and CD34.
Conclusions. Within the results encountered, the present panel should be of great assistance in the diagnosis of oral
IMTs. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:749-756)The term inflammatory myofibroblastic tumor (IMT)
has been used to describe a wide and heterogeneous
group of spindle-cell proliferations, ranging from reac-
tive lesions to benign neoplasms and lesions that be-
have more aggressively or even in a malignant way.1
Such lesions present different histologic patterns, but
are mainly composed of a myofibroblastic cellular pop-
ulation accompanied by a varying number of inflam-
matory cells, chiefly lymphocytes and plasma cells.2
The diagnosis of IMT is performed under light micro-
scope and through immunohistochemistry by a panel of
specific antibodies, such as vimentin, –smooth muscle
actin (SMA), muscle-specific actin (MSA), desmin,
cytokeratins, CD68, and fibronectin (FN).2-4
Owing to the uncertain pathogenesis of IMT and its
several histologic features, a large number of appellations,
such as plasma cell granuloma, plasma cell pseudotumor,
inflammatory myofibrohistiocytic proliferation, omental
mesenteric myxoid hamartoma, inflammatory pseudotu-
mor, and inflammatory fibrosarcoma, have been used to
refer to this entity.2,5
IMTs are commonly found in children and young
adults.3,6 The most frequent anatomic locations are the
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doi:10.1016/j.tripleo.2010.12.023abdominopelvic region, lung, and retroperitoneum,3 but
virtually any site may be involved, including the so-
matic soft tissues, bone, larynx, uterus, and central
nervous system.7-11 Apart from the lung, which is the
most prevalent site for IMT,3 head and neck IMTs
account for 14%-18% of all lesions.3,12
Brooks et al. published a literature review confirming
that IMTs of the oral cavity are rarely encountered13
and, excluding the patients presented herein, only 21
cases appear in the English-language literature.5,9,13-28
The rapid growth rate, as well as the nonspecific
clinical appearance of oral IMTs may resemble that of
malignant disorders. In that way, a comprehensive his-
topathologic assessment should provide precise diag-
nosis.20 Therefore, the present study aimed to describe
the immunophenotype of IMTs of the oral cavity,
which can contribute to the diagnosis of these lesions.
MATERIAL AND METHODS
Using the latest World Health Organization (WHO)
classification of fibroblastic/myofibroblastic tumors,2 3
cases of oral IMTs were retrieved from the consultation
files of the Department of Oral Pathology, University of
São Paulo.
One case of oral squamous cell carcinoma with an
intense desmoplastic area, composed mainly by myo-
fibroblasts,29,30 was selected and functioned as a posi-
tive control of the immunohistochemical reactions.
For conventional light microscopy, tissue was fixed
in 10% buffered formalin, embedded in paraffin wax,
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750 Salgueiredo-Giudice et al. June 2011sectioned at 5 m, and stained with hematoxylin and
eosin.
Sections of 3 m were obtained from the paraffin-
embedded material, mounted on slides, treated with
3-aminopropyltriethoxy-silane (Sigma Chemical Co.,
St. Louis, MO, USA), deparaffinized, and hydrated.
Endogenous peroxidase was quenched by incubation in
3% hydrogen peroxide in methanol (1:1) for 30 minutes
at room temperature. Then sections were treated for
antigen retrieval according to the antibody to be used
(Table I).
Immunohistochemistry was performed on the
Dako Autostainer (Dako Corp., Carpinteria, CA,
USA). Briefly, primary antibodies (Dako) were in-
cubated for 60 minutes. Sources and dilutions for
each antibody are shown in Table I. Incubation with
streptavidin-biotin complex (Kit LSAB Peroxidase
K0690; Dako) followed by 3 minutes’ incubation
with diaminobenzidine (Dako Liquid DAB plus,
K3468; Dako) and subsequent counterstaining with
Mayer hematoxylin. Negative control samples were
treated as above, but using a solution of 1% bovine
serum albumin (BSA) in Tris-HCl, pH 7.4 instead of
the primary antibody.
RESULTS
Clinical findings
The oral sites affected by IMTs were: case 1, tongue
(dorsal side); case 2, alveolar mucosa in the canine-
premolar region (Fig. 1); and case 3, buccal mucosa.
The duration of these lesions was 4, 4, and 5 months,
respectively. The age of the patients ranged from 31 to
Table I. Clone, pretreatment for antigen retrieval, and
dilution of primary antibodies
Antibody Clone Pretreatment* Dilution
Calponin M3556 Citrate 1:150
Caldesmon h-CD Citrate 1:50
ALK ALK1 Citrate 1:50
Bcl-2 124 EDTA 1:100
Desmin D33 Citrate 1:100
Fibronectin — Pepsin 1:1300
CD68 KP1 Citrate 1:400
Ki-67 M1B1 EDTA 1:75
S100 — — 1:700
SMA 1A4 Citrate 1:200
Cytokeratin AE1/AE3 Citrate 1:50
MSA HHF35 Citrate 1:100
CD34 QBEnd10 Citrate 1:50
Vimentin V9 Citrate 1:800
ALK, anaplastic lymphoma kinase; SMA, –smooth muscle actin;
MSA, muscle-specific actin.
*Citrate: 0.01 mol/L, pH 6.0, 95°C, 30 minutes; EDTA: 0.01 mol/L,
pH 9.0, 95°C, 30 minutes; Pepsin: 1%, pH 1.8, 37°C, 60 minutes.60 years old, and 2 of them were women.None of the patients complained of pain. The treat-
ment consisted of surgical excision for all cases. All of
the patients, with 18-48 months of follow-up showed
no sign of recurrence.
Gross findings
Macroscopically, the IMT lesions were fibrotic and
circumscribed, described as nodular masses, with the
color varying from white to light brown. Size ranged
from 1.5 to 5.0 cm in diameter.
Histologic findings
Microscopically, all studied IMTs were in the sub-
mucosa and covered by keratinized and stratified squa-
mous epithelium (Fig. 2, A). All of the tumors were
composed by spindled myofibroblastic cells accompa-
nied by an inflammatory infiltrate mainly constituted by
lymphocytes and a few plasma cells (Fig. 2, B, and Fig.
3, E and I).
Various histologic patterns could be noticed, as de-
scribed by Coffin and Fletcher.2 When analyzing the
morphology of the lesions, some features could also be
mentioned, such as the myofibroblast polymorphism
characterized by elongated spindle (Fig. 3, A) and short
spindle or even stellate cells (Fig. 2, C). The growth
pattern included a fascicular arrangement, and each
lesion demonstrated1 matrix types, which were myx-
oid, fibrotic, or hyalinized (Fig. 2, D). Finally, several
types of vascular arrangements could be noticed within
the stroma. No remarkable nuclear atypia was found.
Immunohistochemical study
The immunohistochemical results are summarized
in Table II. This analysis revealed that the spindle-
Fig. 1. Clinical appearance of inflammatory myofibroblastic
tumor in the alveolar mucosa.shaped cells were strongly and diffusely positive for
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vimentin (3/3; Fig. 3, C, G, and K, and Fig. 4, B) and
MSA (1/3). The expression pattern of calponin
showed a tendency to be at the periphery of the
stained cells’ cytoplasm (Fig. 3, L).
The expression of SMA was accentuated and dif-
fuse in the cytoplasm of spindle-shaped cells (3/3;
Figs. 3, B, F, and J, and 4, C). All the blood vessels
showed positivity to this antibody and functioned as
Fig. 2. A, Morphology of the inflammatory myofibroblastic
and stratified squamous epithelium (hematoxylin-eosin [H
stroma along with a chronic inflammatory infiltrate and h
elongated spindle and short spindle cells with basophilic
collagen bundles (HE, 100).
Table II. Three inflammatory myofibroblastic tumors
carcinoma (D)
Case Calponin ALK CD bcl2 Desmin FN
1      
2      
3      
D      
CD, h-caldesmon; FN, fibronectin; other abbreviations as in Table Ia positive control.As for positivity in the extracellular matrix, FN im-
munohistochemistry revealed positivity staining in all
studied cases (3/3; Fig. 4, D). The immune-staining was
pericellular for the spindle-shaped cells with extracel-
lular extension. The extracellular matrix was mainly
stained on the highly organized collagen bundles. Fi-
nally, vimentin protein was diffusively expressed by
the tumor cells (3/3; Fig. 3, C, G, and K, and Fig. 4, B)
and localized at the periphery of the myofibroblasts’
r revealing a circumscribed tumor covered by a keratinized
100); B, Spindle myofibroblastic cells within the tumor
agic areas (HE, 100); C, Tumor cells characterized by
i (HE, 400); D, Hypocellular area showing hyalinized
, and 3) and desmoplastic area of a squamous cell
8 Ki-67 S100 SMA CK MSA CD34 Vim
      
      
      
      tumo
E], 
emorrh
nucle(1, 2
CD6



cytoplasm (Fig. 4, B).
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CD68, Ki-67, S100, cytokeratins AE1/AE3 (CK), ana-
plastic lymphoma kinase (ALK), and CD34 was absent
in all of the tumor cells.
The oral squamous cell carcinoma revealed, in its
desmoplasic area, positivity for calponin (Fig. 4, A
inset), vimentin (Fig. 4, B inset), SMA (Fig. 4, C inset),
fibronectin (Fig. 4, D inset), and MSA and negativity
for ALK, h-caldesmon, Bcl-2, desmin, CD68, Ki-67,
S100, AE1/AE3, and CD34.
DISCUSSION
Oral IMTs are very rare lesions that may occur pre-
dominantly in the submandibular region,15 the parotid
duct,16,24 the retromolar area,18 the alveolar mucosa of the
molar region,20 tongue,19 and maxilla.16 In contrast to soft
tissue and visceral IMTs, that occur mostly in children and
young adults,3,6 head and neck IMTs are most common in
adults (median age of 59 years) and men.7 Tumor size
usually varies from 0.5 to 5 cm, which was compatible
Fig. 3. The morphology and –smooth muscle actin (SMA), v
tumor cases. Case 1: A, spindle myofibroblasts and chronic
SMA expression within the tumor (100); C, tumor showin
tumor stained by the calponin protein (100). Case 2: E, tum
100); F, myofibroblasts showing positive staining for SMA (
H, calponin expressed by the myofibroblasts (400). Case 3:
infiltrate along with blood vessels (HE100); J, myofibroblas
of vimentin within the tumor (100); L, myofibroblasts showith the present cases.13-16,18,23The literature presents a follow-up that ranges from
1 month to 10 years for oral IMTs, and, including the
present cases, no clinical recurrences are docu-
mented.13,31 Despite the lack of tumor reappearance or
malignant transformation, a prolonged follow-up is
mentioned to be necessary after surgical resection. Re-
garding the most frequent treatments of oral IMTs,
surgical excision,13 radical curettage15 and tumor enu-
cleation25 can be mentioned.
IMTs may display 1 of the 3 histologic patterns
described by WHO within the same tumor,2 as exem-
plified by our cases. Cytologic atypia with nuclear
pleomorphism and increased mitotic activity are un-
common features, and may be associated with malig-
nant transformation.16,20 In the cases presented here, no
remarkable nuclear atypia was found.
Several benign and malignant spindle-cell prolifera-
tions may contribute to the differential diagnosis of
IMT. Among them are proliferative fasciitis, nodular
fasciitis and its homologous lesion referred to as a
in and calponin staining in all 3 inflammatory myofibroblastic
atory infiltrate (hematoxylin-eosin [HE], 400); B, diffuse
se staining pattern of vimentin (100); D, focal area of the
and the stroma infiltrated by chronic inflammatory cells (HE
; G, IMT diffusively expressing the vimentin protein (100);
gated myofibroblastic cells and diffuse chronic inflammatory
ing positive staining for SMA (400); K, diffuse expression
ositive calponin expression (400).iment
inflamm
g diffu
or cells
100)
I, elon
ts showposttraumatic spindle-cell nodule, inflammatory
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bromatosis, Rosai-Dorfman disease, fibrous histiocy-
toma, solitary fibrous tumor, follicular denditric cell
tumor, low-grade myofibroblastic sarcoma, fibrosar-
coma, leiomyosarcoma, rhabdomyosarcoma, and
spindle-cell carcinoma.13
Immunohistochemistry has been a useful tool to dis-
tinguish IMTs from other soft tissue neoplasms.
Among the most applied antibodies, SMA, vimentin,
and FN have shown common positivity for the majority
of the oral and extraoral IMT studied cases.4,13,32-34
Additionally, 1 study has shown that low-grade myo-
fibroblastic sarcomas also express SMA and FN. Other
antibodies, such as ALK and cytokeratin can be used to
differentiate these lesions from IMTs.32
Other neoplastic lesions, such as the solitary fibrous
Fig. 4. Selected positive staining for cases 1, 2, and 3 w
carcinoma for comparison. A, Calponin expression showing
showing the focal desmoplastic area of the carcinoma w
positivity of the myofibroblasts for vimentin in the IM
desmoplastic area of the carcinoma (100). C, Pattern of e
vessels acting as positive control) (100, case 3); inset sho
area of the carcinoma (100). D, Myofibroblasts re
inset—fibronectin diffuse expression in the desmoplastic
(100).tumor shows high CD34 and CD99 positivity rate,35,36while the tumor cells of IMTs do not express these
markers. Alternatively, the diagnosis of spindle cell
carcinoma can be excluded based on AE1/AE3 immu-
nopositivity compared with the IMT cells, which do not
express cytokeratins.37 The cells that mainly character-
ize Rosai-Dorfman disease show immunoreactivity for
S100 protein, differently from the IMT cells.38,39
The follicular dendritic cell tumor shows reactivity to
S100, and along with vimentin, CD21, CD23, CD35
(Ber-MAC-DRC), and Ki-M4 positivity helps in dis-
tinguishing it from IMTs.40-42 In this manner, several
antibodies should provide great assistance for the diag-
nostic process. Fibronectin, for example, has been al-
ready established as a standard marker for the extraoral
IMTs, and its importance on the diagnosis of oral
lesions was recently suggested.4 The present study re-
ets of desmoplastic connective tissue of a squamous cell
use staining pattern within the tumor (100, case 1); inset
myofibroblasts expressing calponin (100). B, Diffuse
100, case 3); inset showing vimentin positivity in the
ion of the –smooth muscle actin in the tumor cells (blood
–smooth muscle actin positivity in the focal desmoplastic
pericellular staining for fibronectin (100, Case 2);
the carcinoma with extension to the extracellular matrixith ins
a diff
ith the
T (
xpress
wing
veal
area ofvealed FN positivity for all cases, this expression being
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of the lesion stroma.
As stated, FN expression is more abundant in the
stroma of benign and malignant soft tissue neo-
plasms,43 but can also appear as intracellular dots in
lung IMT cells44 and in a pericellular mode in IMTs
and low-grade myofibroblastic sarcomas.32 Accord-
ingly, the present study showed FN staining on the cell
surface with extension to the extracellular matrix.
Extraoral IMTs may also be diffusely positive for
MSA.4,13,32-34 Because myofibroblasts contain periph-
eral myofilaments that are effectively stained by the
actin-associated proteins SMA, MSA, and vimen-
tin,4,13,32-34 it was expected to find such expression at
the periphery of the myofibroblast cytoplasm. In fact,
IMTs are collectively positive for SMA (92%)3 and all
the oral tumors studied herein showed expression in the
cytoplasm of the spindle-shaped cells.
Calponin is expressed by myofibroblasts and is a
constituent of smooth muscle thin filaments; therefore,
it is considered to modulate smooth-muscle contrac-
tion.45 IMTs of the urinary bladder have shown posi-
tivity for calponin in the majority of cases, with a range
of 86%-100%.33,34 The expression of calponin in a
recent case of cardiac IMT also helped in diagnosing
the lesion.46 In addition, IMTs arising from lungs,
respiratory tract, abdomen, pelvis, retroperitoneum,
trunk, extremities, and head and neck are positive for
calponin, confirming the effectiveness of this antibody
as an adjuvant in the diagnostic process.32
Our results show that calponin can play an important
role when diagnosing lesions arising from the oral
mucosa. In the present work, the myofibroblasts of all
of the studied tumors showed calponin expression with
enhanced staining at the periphery of their cytoplasms,
as already described in the literature.32 Nevertheless,
calponin is a nonspecific marker that can be positive in
a wide range of myofibroblastic and myoid cells, which
highlights the importance of an adjuvant marker, such
as h-caldesmon, to differentiate myofibroblastic lesions
from smooth-muscle tumors.47
Accordingly, Miettinen et al. noticed the interesting
and simultaneous calponin positivity and h-caldesmon
negativity in all lesions with myofibroblastic differen-
tiation. Those authors therefore proposed the use of
both antibodies in a panel for tumors with myofibro-
blastic differentiation.48 High-molecular-weight calde-
smon (h-caldesmon) is an isoform of caldesmon widely
distributed in smooth and nonsmooth muscle cells and
is thought to regulate cellular contraction.48,49 This
antibody was very useful in guiding the diagnosis of the
cases presented here while differentiating the IMT le-
sions from smooth-muscle neoplasms, such as leiomyo-
mas.49 In addition, fibromatosis, nodular fasciitis, myo-fibroblastic sarcoma, and rhabdomyosarcoma can be
distinguished from smooth-muscle tumors by means of
their h-caldesmon negativity.47,49,50
Overexpression of ALK protein as well as the
proliferation marker Ki-67 and the apoptosis protein
inhibitor Bcl-2 has been correlated with tumorigen-
esis.51-53 Regarding ALK reactivity, a slightly higher
degree of malignant transformation has been related
to the IMTs that shown positivity for this protein.54
On the other hand, Ki-67 nuclear staining can be
associated with aggressive tumoral behavior, multi-
focal origin, and rapid growth of IMTs,52 and Bcl-2
is related to IMT recurrence and malignant transfor-
mation.53
Although none of the present cases showed immu-
noreactivity for Ki-67 antibody, the literature demon-
strates a certain degree of nuclear staining in IMTs.13,23
Nevertheless, Ki-67 expression is generally low for
these tumors (0-10%),31,37 whereas in malignant le-
sions the percentage is usually higher (up to 80%).37
Moreover, the prognostic significance of IMT tumors
that present Ki-67 expression is considered to be am-
bivalent,31 because not all Ki-67–positive IMTs are
related to worse clinical outcomes.52 Nonetheless, all
tumors presented in this study were negative for Ki-67
and had good clinical prognosis with no signs of recur-
rence after the follow-up.
We used an oral squamous cell carcinoma with a
focal area of desmoplastic stroma as control for the
immunohistochemical reactions performed. Desmo-
plastic stromas of carcinomas are mainly composed of
myofibroblasts or myofibroblastic cells and the deposi-
tion of extracellular matrix proteins.29,30 As expected,
the myofibroblasts were positive for calponin, fibronec-
tin, SMA, MSA, and vimentin.
The oral IMTs seem to behave differently from the
ones that occur in other anatomic sites, once they do not
produce significant systemic symptoms nor are detected
with routine blood investigations.16 The basic compo-
nents though, are the myofibroblastic cells, which have
to be identified within the characteristic stroma of the
lesion. Thus, the present study demonstrated the immu-
nohistochemical profile of oral IMTs and the consistent
staining pattern of myofibroblast-associated markers
while identifying the characteristic tumor cells. Such an
immunohistochemical panel should be of great assis-
tance in the diagnosis of oral IMTs.
The authors thank Dr. João Felipe M. Santos for sending
a clinical picture of one of the IMT cases.
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